Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) Equity Average (2018 - 2025)

VYNE Therapeutics (VYNE) has disclosed Equity Average for 8 consecutive years, with $33.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average fell 42.36% year-over-year to $33.3 million, compared with a TTM value of $33.3 million through Dec 2025, down 42.36%, and an annual FY2025 reading of $39.9 million, down 43.3% over the prior year.
  • Equity Average was $33.3 million for Q4 2025 at VYNE Therapeutics, down from $41.5 million in the prior quarter.
  • Across five years, Equity Average topped out at $86.1 million in Q1 2024 and bottomed at $14.4 million in Q3 2023.
  • Average Equity Average over 5 years is $51.8 million, with a median of $52.0 million recorded in 2022.
  • The sharpest move saw Equity Average plummeted 67.46% in 2023, then soared 380.96% in 2024.
  • Year by year, Equity Average stood at $53.8 million in 2021, then tumbled by 33.71% to $35.6 million in 2022, then surged by 40.65% to $50.1 million in 2023, then grew by 15.35% to $57.8 million in 2024, then plummeted by 42.36% to $33.3 million in 2025.
  • Business Quant data shows Equity Average for VYNE at $33.3 million in Q4 2025, $41.5 million in Q2 2025, and $48.1 million in Q1 2025.